The bill amends the New Mexico Controlled Substances Act to align the scheduling of crystalline polymorph psilocybin with federal law. Specifically, it introduces a new provision stating that upon rescheduling by the United States Food and Drug Administration (FDA), crystalline polymorph psilocybin will be scheduled and listed in accordance with federal regulations. This change is intended to ensure that state law reflects any updates made at the federal level regarding the classification of this substance.

Additionally, the bill modifies the existing Schedule I controlled substances list to include a provision that psilocybin will be exempt from the Schedule I classification immediately upon its rescheduling by the FDA. This means that while psilocybin is currently classified as a controlled substance, it will not remain in that category if federal regulations change. The bill aims to streamline the process of updating state law in response to federal actions regarding controlled substances.

Statutes affected:
introduced version: 30-31-3, 30-31-6